Gilead Sciences Inc. (GILD) Earns Consensus Hold Rating

341

 

Gilead Sciences Inc. (GILD) down -13.46 per cent in the past week, is under coverage of 25 analysts who collectively recommend a hold rating on stock. 17 of the analysts have a buy or better rating; the 8 sells versus 0 holds. The 21 equity analysts who rate the stock have an average target price at $111.48, with individual targets ranging between $81 and $135. The shares closed last trade at $88.21, implying that analysts see shares rising about 26.38 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -12.41 down so far this year. A EVP, Corp & Med Affairs at Gilead Sciences Inc. (GILD) sold shares in the company in a transaction completed on Tuesday April 19, 2016. Alton Gregg H offloaded 40,000 shares in the company at an average price of $100.01 and ended up generating $4,000,574 in proceeds. Alton Gregg H retains 137,964 shares in the company after this transaction. A President and CEO in the company, Milligan John F, on Monday April 04, 2016 collected $10,593,904 from the sale of 112,000 shares at $100.01 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering GILD stock at the going market price of $88.21/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $3 in earnings per share (EPS). That would represent a -4.76% year-over-year decrease Revenue for the same period is expected to arrive at $7.83B.

Earnings Roundup: In the last fiscal quarter alone, Gilead Sciences Inc. generated around $7.79B in revenue and net income of $3.03/share. That compares with the consensus estimate $8.12B and $3.15/share, respectively. For the three months through December 2015, revenue for the company hit $8.51B, with earnings at $3.32/share.

Analyst Coverage: Maxim Group has been a brokerage house following shares of Gilead Sciences Inc. (GILD), so its rating change is noteworthy. The stock was downgraded to Hold from Buy, wrote analysts at Maxim Group, in a note issued to clients on Friday April 29, 2016. There was another key note issued by BofA/Merrill on Friday January 15, 2016. The firm lifted its rating on GILD from Underperform to Neutral.

Price Momentum: Despite the -9.06% decrease in value, the stock’s new closing price represents a -27.56% fall in value from company’s one year high of $123.37. The stock is currently holding below its 50 day moving average of $94.9 and below its 200 day moving average of $97.24. Over the last three months and over the last six months, the shares of Gilead Sciences Inc. (GILD), have changed 6.79% and -17.68, respectively.

 

LEAVE A REPLY